Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Cryo Cell International Inc (OTCQB:CCEL) Chairman and Co-CEO David Portnoy acquired 5,826 shares of common stock on August 14, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were purchased at a price of $4.1719, for a total transaction value of $24,305. The purchase comes as the stock trades near its 52-week low of $4.09, having declined about 15% in the past week. InvestingPro data shows the company offers a substantial 14.2% dividend yield.
Following the transaction, Portnoy directly and indirectly owns 1,715,071 shares of Cryo Cell International Inc. While the company faces some near-term challenges, InvestingPro analysis reveals 7 additional investment tips and extensive financial metrics that could help investors make informed decisions about this stock.
In other recent news, Cryo-Cell International, Inc. announced it will suspend its quarterly cash dividend for the third quarter of fiscal 2025. The decision comes amid concerns over lower-than-expected profitability. The company noted that future decisions regarding dividends will be influenced by its financial performance, capital needs, and strategic objectives. This development highlights the company’s focus on managing its financial resources effectively under current conditions. Investors may need to consider these changes as they evaluate Cryo-Cell’s financial outlook. The announcement underscores the importance of profitability in determining dividend policies. While Cryo-Cell did not provide specific financial figures, the move signals a cautious approach to resource allocation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.